Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing
Arulogun, S. O. Brian, D. Goradia, H. Cooney, A. Menne, T. Koo, R. O'Neill, A. T. Vos, J. M. I. Pratt, G. Turner, D.
Arulogun, S. O.
Brian, D.
Goradia, H.
Cooney, A.
Menne, T.
Koo, R.
O'Neill, A. T.
Vos, J. M. I.
Pratt, G.
Turner, D.
Citations
Altmetric:
Abstract
Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinaemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival. A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicentre, retrospective cohort analysis. Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p<0.001). Depth of response impacted survival outcomes: two-year predicted PFS rates after achieving CR/VGPR vs PR were 96% vs 82%, respectively (p=0.002). Total bendamustine dose was predictive of PFS: in the frontline setting, PFS was superior in the group receiving ≥1000mg/m2 compared with those receiving 800-999mg/m2 (p=0.04). In the relapsed cohort, those who received doses of <600mg/m2 had poorer PFS outcomes compared with those who received ≥600mg/m2 (p=0.02). Attaining CR/VGPR following BR results in superior survival, and total bendamustine dose significantly impacts response and survival outcomes, in both frontline and relapsed settings.
Authors
Arulogun, S. O.
Brian, D.
Goradia, H.
Cooney, A.
Menne, T.
Koo, R.
O'Neill, A. T.
Vos, J. M. I.
Pratt, G.
Turner, D.
Marshall, K.
Manos, K.
Anderson, C.
Gavriatopoulou, M.
Kyriakou, C.
Kersten, M. J.
Minnema, M. C.
Koutoumanou, E.
El-Sharkawi, D.
Linton, Kim M
Talaulikar, D.
McCarthy, H.
Bishton, M.
Follows, G.
Wechalekar, A.
D'Sa, S. P.
Brian, D.
Goradia, H.
Cooney, A.
Menne, T.
Koo, R.
O'Neill, A. T.
Vos, J. M. I.
Pratt, G.
Turner, D.
Marshall, K.
Manos, K.
Anderson, C.
Gavriatopoulou, M.
Kyriakou, C.
Kersten, M. J.
Minnema, M. C.
Koutoumanou, E.
El-Sharkawi, D.
Linton, Kim M
Talaulikar, D.
McCarthy, H.
Bishton, M.
Follows, G.
Wechalekar, A.
D'Sa, S. P.
Description
Date
2023
Publisher
Collections
Keywords
Type
Article
Citation
Arulogun SO, Brian D, Goradia H, Cooney A, Menne T, Koo R, et al. Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing. American journal of hematology. 2023 Mar 3. PubMed PMID: 36866925. Epub 2023/03/04. eng.